Health Canada approves first functional cure for chronic hepatitis B
The drug bepirovirsen offers a short-term injection course that can lead to undetectable virus levels for some patients.
Health Canada has approved a new drug that provides the first functional cure for some people with chronic hepatitis B. The treatment, developed by GSK, is expected to be available in early 2027. Clinical trial data showed the drug cleared all detectable traces of the virus from the blood in about one-fifth of participants. Dr. Carla Coffin, a hepatologist at the University of Calgary, called it a major step forward. She cautioned that the drug is effective for only a minority of patients and its long-term durability, cost and access remain uncertain.
The hepatitis B virus is transmitted through bodily fluids like blood and semen, and can become a lifelong infection if contracted in childhood. An estimated 260,000 Canadians live with the virus, with half unaware of their status. Chronic infection can lead to liver cancer or failure over time. Higher rates are found among Indigenous communities, immigrants from endemic countries, people who use injection drugs and those engaging in high-risk sexual activity.
Current standard care involves lifelong antiviral medication to suppress the virus. This new treatment, called bepirovirsen, is a short-term injection course. Dr. Curtis Cooper, head of the Ottawa Hospital's viral hepatitis program, said it completely clears all of the viral markers for hepatitis B out of the blood. He said it offers quite a bit of hope for patients aiming to discontinue other treatments.
READ MORE: Health Canada approves Skyrizi for pediatric psoriasis
Eligibility for the treatment is limited. Coffin said clinicians must carefully select patients who would benefit. Individuals with cirrhosis, or permanent liver scarring, are not eligible. The injections can cause more side effects, such as a rash, compared to daily oral antivirals. The latest follow-up data shows the treatment's effects last at least 96 weeks, but longer-term outcomes are unknown. Our expectation is that it will last, Coffin said. But of course, we won't know that until we do the long-term follow-up in these patients.
Dr. Eric Yoshida, a gastroenterology professor at the University of British Columbia, raised concerns about cost and access. In Japan, where the drug is already approved, a course costs roughly $84,000 Canadian. Yoshida questioned whether provincial drug plans and private insurers will cover it in Canada. Looking into the future, well, this is the first generation. The next generation is probably going to be even better and even less expensive, so I think the future is looking bright, Yoshida said. But I think for the average Canadian patient with hepatitis B, it's probably not going to mean a heck of a lot.
Both experts emphasized that vaccination remains the key to eliminating hepatitis B. In November, Canada's national vaccine advisory committee recommended all infants receive the hepatitis B shot. This contrasts with a recent move in the United States to drop its universal newborn vaccination recommendation. Globally, 75 percent of hepatitis B-related deaths in 2024 occurred in Africa and the Western Pacific, according to the World Health Organization. If every country in the world vaccinated their newborns, said Yoshida, I think hepatitis B would be basically on the way out. Coffin added, We still have a long way to go.
With files from CBC News
Amara Okafor covers health, medical research and public health in Canada for Novello Desserts.